Marple brings more than 20 years of experience as a senior executive with broad skill sets across clinical development, IP protection, and manufacturing.
U.S.-based, state-of-the-art facilities to be established for sustainable production of adjuvanted recombinant vaccine for use in the event of a pandemic.